Iovance Biotherapeutics, Inc.
IOVA
Rangering i aksjer
#2783
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aksjekurs
$14.87
Sist synkronisert: 2026-10-20
Markedsverdi
$6.74B
Endring (1 dag)
4.64%
Endring (1 år)
555.03%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
P/E-forhold for Iovance Biotherapeutics, Inc. (IOVA)
P/E-forhold per October 2026 TTM: -19.47
Ifølge Iovance Biotherapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -19.47. Ved slutten av 2023 hadde selskapet en P/E på -4.31.
P/E-forholdshistorikk for Iovance Biotherapeutics, Inc. fra 2008 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -19.47 | 237.95% |
| 2024 | -5.76 | 33.88% |
| 2023 | -4.31 | 67.47% |
| 2022 | -2.57 | -69.96% |
| 2021 | -8.56 | -65.39% |
| 2020 | -24.72 | 41.90% |
| 2019 | -17.42 | 150.08% |
| 2018 | -6.97 | 22.88% |
| 2017 | -5.67 | -21.93% |
| 2016 | -7.26 | -41.41% |
| 2015 | -12.40 | -24.14% |
| 2014 | -16.34 | 304.54% |
| 2013 | -4.04 | -23.95% |
| 2012 | -5.31 | 79.73% |
| 2011 | -2.95 | -94.17% |
| 2010 | -50.72 | -99.21% |
| 2009 | -6.45K | 176.01% |
| 2008 | -2.34K | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 28.78 | -247.86% |
US
|
|
| -28.36 | 45.68% |
US
|
|
| -24.57 | 26.21% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -255.81% |
NL
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.